__link__ - Pda Technical Report 82

The report clarifies that but a validated alternative for constrained systems. It emphasizes that this method is often necessary to prevent mechanical failure (e.g., pump damage) that might occur if the system is forced to run at high velocity while hot.

: Failure to include LER risk assessment can lead to regulatory submission deficiencies, review delays, or post-approval commitments

Recognizing the specialized expertise required, multiple contract research organizations now offer LER hold-time studies conducted “in accordance with PDA Technical Report 82,” utilizing both chronological and reverse-spike methodologies to support BLA and MAA submissions.

PDA Technical Report 82 was created to provide a structured approach to managing this phenomenon in the pharmaceutical industry. Key goals include: pda technical report 82

In keeping with PDA’s commitment to rigorous scientific consensus, the draft report underwent an exceptionally thorough review involving . This multi-stage review process, documented at every level of comment resolution, ensures that TR 82 represents not merely one company’s perspective but the collective wisdom of the entire parenteral drug community.

Provide a detailed list of your LER study.

The revised TR 82 will likely address:

LER can be driven by interactions between endotoxins and the drug product matrix. The report suggests that endotoxins may be affected by:

Offering guidance on how to properly design hold-time studies.

A significant portion of the report addresses the risk of biofilm. The report clarifies that but a validated alternative

: Guidance addresses time points (T0, 1 day, 3 days, 7 days, 14 days or longer), container types (with borosilicate glass tubes depyrogenated at 250°C recommended to minimize adsorption), and storage temperatures.

If LER is detected (i.e., endotoxin recovery falls below 50% at any time point), manufacturers should: